MicroPharm Ltd.

MicroPharm Ltd. is a commercial and clinical-stage specialty pharmaceutical company based in Newcastle Emlyn, West Wales, United Kingdom. The company describes itself as focused on the development and commercialisation of specifically targeted polyclonal antibodies, built around several proprietary technology platforms. Its operations span the full manufacturing chain for antibody-based medicines: purification of serum and plasma, final formulation, sterile filling and packaging. MicroPharm operates two manufacturing sites in West Wales, both licensed by the UK Medicines and Healthcare products Regulatory Agency (MHRA). MicroPharm's commercialised products are antivenoms for human use, which are sold in Europe, the Caribbean and West Africa. Its marketed portfolio includes EchiTAbG™, BOTHROFAV® and VIPERFAV®. These antivenoms are used in the clinical management of envenoming from snakebites, a significant public-health issue in parts of Africa, Asia and Latin America. Beyond its marketed antivenoms, MicroPharm has a development pipeline that reflects its polyclonal antibody platform. Products in development include an orally delivered polyclonal antibody drug for the treatment of Clostridioides difficile infection, known as OraCAb®, and two polyvalent antivenoms — one intended for use in sub-Saharan Africa and another for North Africa and the Middle East. The pipeline also lists Favirept® and Fav-Afrique®. As a specialty pharmaceutical company, MicroPharm occupies a niche at the intersection of plasma-derived medicines and neglected-disease therapeutics. Its antivenom products are particularly relevant to low- and middle-income countries where snakebite envenoming remains a major cause of morbidity and mortality. The company's dual role as both a licensed manufacturer and a developer of new antibody therapies positions it as a specialist supplier in the global antivenom and polyclonal antibody market.

MicroPharm Ltd. is a specialty pharmaceutical company located in Newcastle Emlyn, West Wales, United Kingdom. Public information about the company's founding date and founders is limited in the available evidence; the company is documented as a UK company in Newcastle Emlyn. Its core identity is built around the development and commercialisation of specifically targeted polyclonal antibodies, supported by several proprietary technology platforms. MicroPharm's manufacturing base consists of two sites in West Wales, both licensed by the Medicines and Healthcare products Regulatory Agency (MHRA). The company's manufacturing capabilities cover the purification of serum and plasma through to final formulation, sterile filling and packaging — an integrated approach that allows it to produce plasma-derived antibody products in-house. The company's commercialised products are antivenoms for human use, sold in Europe, the Caribbean and West Africa. Its marketed antivenoms include EchiTAbG™, BOTHROFAV® and VIPERFAV®. These products address snakebite envenoming, a condition that disproportionately affects rural populations in tropical and subtropical regions. MicroPharm has continued to invest in its pipeline. Its development programmes include an orally delivered polyclonal antibody drug for the treatment of Clostridioides difficile infection, known as OraCAb®, and two polyvalent antivenoms — one for sub-Saharan Africa and one for North Africa and the Middle East. The pipeline also lists Favirept® and Fav-Afrique®. These programmes illustrate the company's strategy of leveraging its polyclonal antibody platform across both infectious disease and envenoming indications. As a private UK specialty pharmaceutical company, MicroPharm operates in a niche market with high regulatory barriers. Its MHRA-licensed manufacturing and its focus on antivenoms for underserved markets position it as a specialist supplier in the global plasma-derived therapeutics and antivenom sectors.

Specialty pharmaceutical company focused on targeted polyclonal antibodies and antivenoms, with MHRA-licensed manufacturing in West Wales.

• EchiTAbG™

  A commercialised antivenom for human use, sold in Europe, the Caribbean and West Africa.

• BOTHROFAV®

  A commercialised antivenom for human use, sold in Europe, the Caribbean and West Africa.

• VIPERFAV®

  A commercialised antivenom for human use, sold in Europe, the Caribbean and West Africa.

• OraCAb®

  An orally delivered polyclonal antibody drug in development for the treatment of Clostridioides difficile infection.

• Favirept®

  A product listed in MicroPharm's development pipeline.

• Fav-Afrique®

  A product listed in MicroPharm's development pipeline.

1. 1Micropharmmicropharm.co.uk
2. 2Products -micropharm.co.uk
3. 3Product Pipeline - Micropharmmicropharm.co.uk
4. 4MicroPharm Ltd. (United Kingdom)wikidata.org